✨
AI Summary
- Nemolizumab sustained positive outcomes in moderate to severe atopic dermatitis for three years.
- Long-term data showed continued improvements in skin clearance, itch, and quality of life.
- Sustained response suggests nemolizumab's potential for long-term management of AD.
